A forum for researchers, students and applicants in the field of cyclodextrin technology
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced positive
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, delivered eight
Amgen (NASDAQ:AMGN) recently announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)
Development of generic formulations with cyclodextrins for oral delivery has been neglected for several decades, since the CD-enabled formulations often
Amgen announced on the 27th August, 2018 the submission of a supplemental New Drug Application (sNDA) to the U.S. Food
Recently, a new patent application became accessible to the public, WO2018146698 (A1), filed by Biophore India, a DMF holder for the
Starting from the discovery of cyclodextrins (“cellulosines” at that time) by Villiers in 1891 the history of cyclodextrin research is
For those, interested in building relationships with industrial partners as well as broadening their knowledge in state-of-the-art academic research, AAPS
If you are following advances in the re-discovery of cyclodextrins as APIs, there is quite a race among the candidates
